GlassScriptPhysician profile
Neisa Torres Reyes
NPI 1629016829
$7,996.99
in general payments reported to CMS, 2019-2025
26 companies · $1,766 in 2025
The $1,766 reported for 2025 was more than what 93% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,052 · 2020: $193 · 2021: $412 · 2022: $781 · 2023: $2,415 · 2024: $1,378 · 2025: $1,766.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,751 · Consulting Fee: $1,500 · Education: $308.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,750.87 |
| Consulting Fee | $1,500.00 |
| Education | $308.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $2,077.79 | 2019-2025 | Winrevair, Capvaxive, Gardasil 9 |
| Astrazeneca Pharmaceuticals LP | $1,302.17 | 2019-2025 | Tezspire, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $1,043.49 | 2019-2025 | Trelegy Ellipta, Nucala |
| Boehringer Ingelheim Pharmaceuticals, INC. | $815.41 | 2019-2025 | Ofev, Jascayd |
| Viatris Specialty LLC | $281.90 | 2025 | Yupelri |
| Mylan Specialty L.P. | $247.80 | 2022-2024 | Yupelri |
| Genzyme Corporation | $235.44 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $231.10 | 2021-2025 | Glassia, Hyqvia |
| Amgen INC. | $225.50 | 2022-2025 | Tezspire, Prolia, Repatha |
| Janssen Pharmaceuticals, INC | $214.56 | 2019-2025 | Uptravi, Opsumit, Xarelto |
| Mallinckrodt Hospital Products INC. | $183.98 | 2024-2025 | Acthar |
| Gilead Sciences, INC. | $164.41 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $159.84 | 2019-2023 | |
| Grifols USA, LLC | $128.95 | 2019 | |
| Terumo Medical Corporation | $117.15 | 2025 | Access |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $112.93 | 2019-2023 | Opsumit, Uptravi |
| Genentech USA, INC. | $67.23 | 2019 | |
| Abbott Laboratories | $62.49 | 2019-2022 | |
| Jazz Pharmaceuticals INC. | $60.00 | 2024-2025 | |
| Pfizer INC. | $58.90 | 2023-2025 | |
| Shire North American Group INC | $47.85 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $42.86 | 2019 | |
| Mylan LLC | $41.38 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $31.58 | 2021 | |
| Pbg Puerto Rico LLC | $25.00 | 2023 | |
| United Therapeutics Corporation | $17.28 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Neisa Torres Reyes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.